Literature DB >> 25987626

Risk Factors for Acquisition and Loss of Clostridium difficile Colonization in Hospitalized Patients.

Erik R Dubberke1, Kimberly A Reske2, Sondra Seiler2, Tiffany Hink2, Jennie H Kwon2, Carey-Ann D Burnham3.   

Abstract

Asymptomatic colonization may contribute to Clostridium difficile transmission. Few data identify which patients are at risk for colonization. We performed a prospective cohort study of C. difficile colonization and risk factors for C. difficile acquisition and loss in hospitalized patients. Patients admitted to medical or surgical wards at a tertiary care hospital were enrolled; interviews and chart review were performed to determine patient demographics, C. difficile infection (CDI) history, medications, and health care exposures. Stool samples/rectal swabs were collected at enrollment and discharge; stool samples from clinical laboratory tests were also included. Samples were cultured for C. difficile, and the isolates were tested for toxins A and B and ribotyped. Chi-square tests and univariate logistic regression were used for the analyses. Two hundred thirty-five patients were enrolled. Of the patients, 21% were colonized with C. difficile (toxigenic and nontoxigenic) at admission and 24% at discharge. Ribotype 027 accounted for 6% of the strains at admission and 12% at discharge. Of the patients colonized at admission, 78% were also colonized at discharge. Cephalosporin use was associated with C. difficile acquisition (47% of patients who acquired C. difficile versus 25% of patients who did not; P = 0.03). β-lactam-β-lactamase inhibitor combinations were associated with a loss of C. difficile colonization (36% of patients who lost C. difficile colonization versus 8% of patients colonized at both admission and discharge; P = 0.04), as was metronidazole (27% versus 3%; P = 0.03). Antibiotic use affects the epidemiology of asymptomatic C. difficile colonization, including acquisition and loss, and it requires additional study.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25987626      PMCID: PMC4505269          DOI: 10.1128/AAC.00642-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  54 in total

1.  Metronidazole may inhibit intestinal colonization with Clostridium difficile.

Authors:  R K Cleary; R Grossmann; F B Fernandez; T S Stull; J J Fowler; M R Walters; R M Lampman
Journal:  Dis Colon Rectum       Date:  1998-04       Impact factor: 4.585

2.  Nosocomial acquisition of Clostridium difficile infection.

Authors:  L V McFarland; M E Mulligan; R Y Kwok; W E Stamm
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

3.  The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients.

Authors:  S R Heard; S O'Farrell; D Holland; S Crook; M J Barnett; S Tabaqchali
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

4.  Prevalence of and risk factors for Clostridium difficile colonization at admission to an infectious diseases ward.

Authors:  Y Hutin; I Casin; P Lesprit; Y Welker; J M Decazes; P Lagrange; J Modaï; J M Molina
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

5.  Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea.

Authors:  J K Shim; S Johnson; M H Samore; D Z Bliss; D N Gerding
Journal:  Lancet       Date:  1998-02-28       Impact factor: 79.321

6.  Clostridium difficile colonization and diarrhea at a tertiary care hospital.

Authors:  M H Samore; P C DeGirolami; A Tlucko; D A Lichtenberg; Z A Melvin; A W Karchmer
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

7.  The prevalence and nosocomial acquisition of Clostridium difficile in elderly hospitalized patients.

Authors:  B Rudensky; S Rosner; M Sonnenblick; Y van Dijk; E Shapira; M Isaacsohn
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

8.  Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial.

Authors:  S Johnson; S R Homann; K M Bettin; J N Quick; C R Clabots; L R Peterson; D N Gerding
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

9.  Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

Authors:  C R Clabots; S Johnson; M M Olson; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

10.  Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea.

Authors:  M H Samore; L Venkataraman; P C DeGirolami; R D Arbeit; A W Karchmer
Journal:  Am J Med       Date:  1996-01       Impact factor: 4.965

View more
  21 in total

1.  Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Authors:  Mark D Gonzalez; Meghan A Wallace; Tiffany Hink; Erik R Dubberke; Carey-Ann D Burnham
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

2.  Detection of Clostridium difficile in Feces of Asymptomatic Patients Admitted to the Hospital.

Authors:  Elisabeth M Terveer; Monique J T Crobach; Ingrid M J G Sanders; Margreet C Vos; Cees M Verduin; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2016-11-16       Impact factor: 5.948

3.  An Evaluation of the Prevalence of Vancomycin-Resistant Enterococci (VRE) and Methicillin-Resistant Staphylococcus aureus (MRSA) in Hospital Food.

Authors:  Jennie H Kwon; Kimberly A Reske; Tiffany Hink; Sondra M Seiler; Meghan A Wallace; Kerry M Bommarito; Carey-Ann D Burnham; Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2017-09-27       Impact factor: 3.254

4.  An Evaluation of Food as a Potential Source for Clostridium difficile Acquisition in Hospitalized Patients.

Authors:  Jennie H Kwon; Cristina Lanzas; Kimberly A Reske; Tiffany Hink; Sondra M Seiler; Kerry M Bommarito; Carey-Ann D Burnham; Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2016-10-03       Impact factor: 3.254

Review 5.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

6.  Clostridium difficile colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea.

Authors:  Erik R Dubberke; Kimberly A Reske; Tiffany Hink; Jennie H Kwon; Candice Cass; Jahnavi Bongu; Carey-Ann D Burnham; Jeffrey P Henderson
Journal:  Infect Control Hosp Epidemiol       Date:  2018-09-18       Impact factor: 3.254

7.  Evaluating a Pharmacy-Driven 72-Hour Antibiotic Monitoring Program Implemented in a Community Hospital.

Authors:  Vishal Patel; Shaina Doyen
Journal:  Hosp Pharm       Date:  2019-08-06

8.  Prevalence of Clostridium difficile infection and colonization in a tertiary hospital and elderly community of North-Eastern Peninsular Malaysia.

Authors:  N H Zainul; Z F Ma; A Besari; H Siti Asma; R A Rahman; D A Collins; N Hamid; T V Riley; Y Y Lee
Journal:  Epidemiol Infect       Date:  2017-09-11       Impact factor: 4.434

9.  Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?

Authors:  Sirisha Kundrapu; Venkata C K Sunkesula; Lucy A Jury; Jennifer L Cadnum; Michelle M Nerandzic; Jackson S Musuuza; Ajay K Sethi; Curtis J Donskey
Journal:  BMC Infect Dis       Date:  2016-04-18       Impact factor: 3.090

10.  Colonization of toxigenic Clostridium difficile among ICU patients: a prospective study.

Authors:  Xiaoxia Zhang; Xiaohui Wang; Jingyu Yang; Xiaohua Liu; Lin Cai; Zhiyong Zong
Journal:  BMC Infect Dis       Date:  2016-08-09       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.